Drug & Salt Regulations
USP–NF Compendial Compliance: Elemental Impurities <232>/<233> & Dissolution Testing for Oral Salts
Compendial enforcement notice for bulk pharmaceutical salts and finished tablets exported to USP-recognized jurisdictions. All drug products must demonstrate full alignment with USP General Chapters <232> and <233>, harmonized with ICH Q3D(R2) elemental impurity guidelines.
- Class 1 & 2A Metals: Mandatory ICP-MS or ICP-OES risk assessment covering Cadmium (Cd), Lead (Pb), Arsenic (As), Mercury (Hg), Cobalt (Co), Nickel (Ni), and Vanadium (V) from synthesis catalysts and primary packaging leachables.
- Batch Release: Generic API Certificates of Analysis (COA) must specify analytical method reference, loss on drying (LOD), and residue on ignition thresholds.
Official Source & Verification Reference
Issuing Authority: United States Pharmacopeia (USP) • Reference: USP-NF-232-233-2026
Verify Official Source Document ↗